CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), CSF-2R stimulants(Granulocyte-macrophage colony-stimulating factor receptor stimulants), CTLA4 stimulants(Cytotoxic T-Lymphocyte-Associated Antigen 4 stimulants)

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

RADIENT CONSULTING SRL

Active Organization

RADIENT CONSULTING SRL

Inactive Organization

Radient Pharmaceuticals Corp.

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

100 Clinical Results associated with B7-2/GM-CSF cancer gene therapy(Radient Consulting)

100 Translational Medicine associated with B7-2/GM-CSF cancer gene therapy(Radient Consulting)

100 Patents (Medical) associated with B7-2/GM-CSF cancer gene therapy(Radient Consulting)

Literatures (Medical) associated with B7-2/GM-CSF cancer gene therapy(Radient Consulting)

01 Oct 2011·Journal of Veterinary Pharmacology and TherapeuticsQ3 · AGRICULTURAL & FORESTRY SCIENCE

The pharmacokinetics of hydrochlorothiazide in the camel

Q3 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: I. A. Wasfi ; N.A. Al Katheeri

The purposes of this study were to characterize the pharmacokinetics (PK) of hydrochlorothiazide (HCT) in camels and to develop a sensitive liquid chromatog. tandem mass spectrometry (LC/MS/MS) method for the detection of HCT in camel fluids and to advice on a withdrawal period before camel racing following a therapeutic dose of HCT.Hydrochlorothiazide resulted in profound urine production in camels but no adverse effects were observedThe AUC_0-∞ of the double dose was twice that of the first dose and was significantly different from it.However, V_ss, CI_T, T_1/2β and mean residence time were similar in both dose regimens suggesting linear kinetics in the dose range used.The LC/MS/MS method used in this study proved to be sensitive and efficient and is superior to HPLC methods that lacked sensitivity and to GC, and GC/MS methods which required cumbersome derivatization steps.He LC-MS/MS method reported in this study, with a LOQ of 2 ng/mL, could easily detect HCT 1-2 days after administration.Therefore, as a precautionary measure due to inter-animal variation, we propose withholding HCT administration before racing for a min. period of 3 days.

01 Dec 1999·European Journal of PharmacologyQ3 · MEDICINE

[3H]β-CIT: a radioligand for dopamine transporters in rat brain tissue

Q3 · MEDICINE

Article

Author: Tarazi, F. I. ; Fisser, R. ; Neumeyer, J. L. ; Wang, S. ; Kula, N. S. ; Trometer, J. ; Baldessarini, R. J.

[3H]2-beta-carbomethoxy-3-beta-[4'-iodophenyl]tropane (beta-CIT) was prepared and evaluated. With rat forebrain tissue, [3H]beta-CIT showed high affinity for dopamine transporters (DAT), with selectivity for DAT over norepinephrine transporters, but not serotonin transporters, as well as DAT-stereoselectivity with beta-CIT, amphetamine and methylphenidate. Affinity and selectivity for 53 compounds assayed with [3H]beta-CIT and standard DAT radioligand [3H]GBR-12935 were highly correlated (r0.95). [3H]beta-CIT is proposed as a useful, high-affinity DAT radioprobe.

100 Deals associated with B7-2/GM-CSF cancer gene therapy(Radient Consulting)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 2	Canada	Radient Pharmaceuticals Corp.	-
Neoplasms	Phase 1	-	RADIENT CONSULTING SRL	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

B7-2/GM-CSF cancer gene therapy(Radient Consulting)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation